Neocortical developmental analysis of vasculature and their growth factors offer new insight into fragile X syndrome abnormalities
- 27 July 2017
- journal article
- research article
- Published by Wiley in Developmental Neurobiology
- Vol. 77 (11) , 1321-1333
Abstract
Fragile X Syndrome (FXS) is the most common single gene cause for Autism Spectrum Disorder and the most prevalent form of inherited mental retardation. Our prior studies have demonstrated that adult FXS mice have abnormal blood vessel density (BVD) and elevated Vascular Endothelial Growth Factor A expression (VEGF‐A). VEGF‐A is one of the most prominent regulators of BVD, and its abnormal expression is the most likely cause for FXS BVD abnormalities. We have demonstrated that attenuating elevated VEGF‐A expression can ameliorate many non‐vascular FXS abnormalities (Belagodu, Zendeli Slater and Galvez: Dev Neurobiol 77 (2017) 14–25), suggesting that abnormal VEGF‐A expression is an underlying cause for some FXS abnormalities. However, FXS is a developmental disorder and VEGF‐A's potential role in mediating FXS abnormalities during development have never been explored. Furthermore, VEGF‐A is one protein in a family of proteins (VEGF‐A, VEGF‐B, VEGF‐C, VEGF‐D, & PLGF) that activate one of three primary receptors (VEGFR1, VEGFR2, & VEGFR3). Abnormal expression of any of these proteins could hinder proper development. The current study demonstrated that FXS mice do not exhibit normal BVD developmental patterns, resulting in elevated adult expression, most likely due to observed elevated VEGF‐A adult expression. Interestingly, all five VEGF family of proteins exhibited altered developmental expression patterns that could cause abnormal development. However, none of the receptors exhibited abnormal adult expression, but did exhibit altered developmental expression. Expanding upon our prior analyses, the current study provides additional interesting insight towards potential developmental mechanisms mediating FXS abnormalities, while offering further sites for age specific therapeutic interventions. © 2017 Wiley Periodicals, Inc. Develop Neurobiol 77: 1321–1333, 2017Keywords
Funding Information
- National Science Foundation (0903622)
- Jerome Lejeune Foundation
This publication has 70 references indexed in Scilit:
- The Synaptic Proteome during Development and Plasticity of the Mouse Visual CortexMolecular & Cellular Proteomics, 2011
- Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterizationJournal of Neurodevelopmental Disorders, 2010
- Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndromeProceedings of the National Academy of Sciences, 2010
- Stimulatory Effects of Thyroid Hormone on Brain Angiogenesis in vivo and in vitroJournal of Cerebral Blood Flow & Metabolism, 2009
- Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injuryExperimental Neurology, 2008
- Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapsesMolecular and Cellular Neuroscience, 2006
- The mGluR theory of fragile X mental retardationTrends in Neurosciences, 2004
- Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endotheliumNature, 1995
- Absence of expression of the FMR-1 gene in fragile X syndromeCell, 1991
- Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndromeCell, 1991